Early HTA in Pharmacogenomics: A Case Example in Cardiovascular Drugs

Value in Health - United Kingdom
doi 10.1016/j.jval.2016.09.1668
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pharmacogenomics in Early-Phase Clinical Development

Pharmacogenomics
Molecular MedicineGeneticsPharmacology
2013English

Are Orphan Drugs Treated the Same Across Europe: An Hta Case Study

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Hta Studies on Orphan Drugs by Rebratsxmembers

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Drugs and Cardiovascular Risk in Inflammatory Arthritis: Another Case of Glucocorticoid-Bashing?

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2015English

Blood Biomarkers for Memory: Toward Early Detection of Risk for Alzheimer Disease, Pharmacogenomics, and Repurposed Drugs

Molecular Psychiatry
PsychiatryMolecular NeuroscienceMental HealthMolecular BiologyCellular
2019English

PPAR Genomics and Pharmacogenomics: Implications for Cardiovascular Disease

PPAR Research
Drug DiscoveryPharmacology
2008English

Pcn322 - An Example of Rwe Used for Hta Evaluation: Erlotinib Renegotiation in Italy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Reimbursement Decision Landscape for Orphan Drugs Across Six Hta Agencies

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Pharmacogenomics in Early-Phase Oncology Clinical Trials: Is There a Sweet Spot in Phase II?

Clinical Cancer Research
Cancer ResearchOncology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy